Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Apropå! Immunitet mot mässling.

Hallander HO, Ljungman M.

Lakartidningen. 2018 Feb 2;115. pii: EZSZ. Swedish. No abstract available.

2.

[New whooping cough deaths].

Hallander HO.

Lakartidningen. 2016 Mar 21;113. pii: DYHY. Swedish. No abstract available.

3.
4.

[Whooping cough--time to reconsider the vaccination program].

Hallander HO.

Lakartidningen. 2015 Jun 23;112. pii: DI6X. Swedish. No abstract available.

5.

Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.

Carlsson RM, Gustafsson L, Hallander HO, Ljungman M, Olin P, Gothefors L, Nilsson L, Netterlid E.

Vaccine. 2015 Jul 17;33(31):3717-25. doi: 10.1016/j.vaccine.2015.05.079. Epub 2015 Jun 7.

PMID:
26057135
6.

Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012.

van Gent M, Heuvelman CJ, van der Heide HG, Hallander HO, Advani A, Guiso N, Wirsing von Kőnig CH, Vestrheim DF, Dalby T, Fry NK, Pierard D, Detemmerman L, Zavadilova J, Fabianova K, Logan C, Habington A, Byrne M, Lutyńska A, Mosiej E, Pelaz C, Gröndahl-Yli-Hannuksela K, Barkoff AM, Mertsola J, Economopoulou A, He Q, Mooi FR.

Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):821-30. doi: 10.1007/s10096-014-2297-2. Epub 2014 Dec 20.

7.

Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.

Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, Hallander HO, Wirsing von Konig CH, Riffelman M, Storsaeter J, Vestrheim DF, Dalby T, Krogfelt KA, Fry NK, Barkoff AM, Mertsola J, He Q, Mooi F.

Euro Surveill. 2014 Aug 21;19(33). pii: 20881.

8.

Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.

Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, Cassiday PK, Chiang CS, Dalby T, Fry NK, Gaillard ME, van Gent M, Guiso N, Hallander HO, Harvill ET, He Q, van der Heide HG, Heuvelman K, Hozbor DF, Kamachi K, Karataev GI, Lan R, Lutyńska A, Maharjan RP, Mertsola J, Miyamura T, Octavia S, Preston A, Quail MA, Sintchenko V, Stefanelli P, Tondella ML, Tsang RS, Xu Y, Yao SM, Zhang S, Parkhill J, Mooi FR.

MBio. 2014 Apr 22;5(2):e01074. doi: 10.1128/mBio.01074-14.

9.

Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.

Advani A, Hallander HO, Dalby T, Krogfelt KA, Guiso N, Njamkepo E, von Könnig CH, Riffelmann M, Mooi FR, Sandven P, Lutynska A, Fry NK, Mertsola J, He Q.

J Clin Microbiol. 2013 Feb;51(2):422-8. doi: 10.1128/JCM.02036-12. Epub 2012 Nov 21.

10.

Is adolescent pertussis vaccination preferable to natural booster infections?

Hallander HO, Nilsson L, Gustafsson L.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):705-11. doi: 10.1586/ecp.11.55. Review.

PMID:
22111856
11.

SNP-based typing: a useful tool to study Bordetella pertussis populations.

van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Kallonen T, He Q, Mertsola J, Advani A, Hallander HO, Janssens K, Hermans PW, Mooi FR.

PLoS One. 2011;6(5):e20340. doi: 10.1371/journal.pone.0020340. Epub 2011 May 27.

12.

Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs.

Advani A, Gustafsson L, Ahrén C, Mooi FR, Hallander HO.

Vaccine. 2011 Apr 18;29(18):3438-42. doi: 10.1016/j.vaccine.2011.02.070. Epub 2011 Mar 9.

PMID:
21396900
13.

Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease.

Hallander HO, Lepp T, Ljungman M, Netterlid E, Andersson M.

APMIS. 2010 Nov;118(11):878-87. doi: 10.1111/j.1600-0463.2010.02674.x. Epub 2010 Sep 2.

PMID:
20955461
14.

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, Ljungman M, Hallander HO.

Clin Vaccine Immunol. 2010 May;17(5):741-7. doi: 10.1128/CVI.00469-09. Epub 2010 Mar 24.

15.

Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.

Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E.

APMIS. 2009 Dec;117(12):912-22. doi: 10.1111/j.1600-0463.2009.02554.x.

16.

[Good immune response of diphtheria-tetanus-pertussis vaccination in the 4th grade. Local reaction very common--and expected].

Nilsson L, Carlsson RM, Hallander HO, Ljungman M, Hallberg M, Storsaeter J.

Lakartidningen. 2009 Sep 16-22;106(38):2357-61. Swedish. No abstract available.

PMID:
19848341
17.

Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.

Hallander HO, Ljungman M, Storsaeter J, Gustafsson L.

APMIS. 2009 Nov;117(11):797-807. doi: 10.1111/j.1600-0463.2009.02530.x.

PMID:
19845530
18.

Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience.

Hallander HO, Gustafsson L.

Expert Rev Vaccines. 2009 Oct;8(10):1303-7. doi: 10.1586/erv.09.88. No abstract available.

PMID:
19803750
19.

Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.

Hallander HO, Ljungman M, Jahnmatz M, Storsaeter J, Nilsson L, Gustafsson L.

APMIS. 2009 Sep;117(9):660-71. doi: 10.1111/j.1600-0463.2009.02521.x.

PMID:
19703126
20.

Analysis of Swedish Bordetella pertussis isolates with three typing methods: characterization of an epidemic lineage.

Advani A, Van der Heide HG, Hallander HO, Mooi FR.

J Microbiol Methods. 2009 Sep;78(3):297-301. doi: 10.1016/j.mimet.2009.06.019. Epub 2009 Jul 3.

PMID:
19577594
21.

Performance of Bordetella pertussis IS481 real-time PCR in a vaccine trial setting.

Gullsby K, Hallander HO, Bondeson K.

APMIS. 2007 Dec;115(12):1370-5. doi: 10.1111/j.1600-0463.2007.00774.x.

PMID:
18184407
22.

Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype.

Advani A, Gustafsson L, Carlsson RM, Donnelly D, Hallander HO.

APMIS. 2007 Jun;115(6):736-42.

PMID:
17550382
23.
24.

Acellular pertussis vaccines and the role of pertactin and fimbriae.

Poolman JT, Hallander HO.

Expert Rev Vaccines. 2007 Feb;6(1):47-56. Review.

PMID:
17280478
25.

Shifts of rotavirus g and p types in Nicaragua--2001-2003.

Espinoza F, Bucardo F, Paniagua M, Svensson L, Hallander HO, Bondeson K.

Pediatr Infect Dis J. 2006 Nov;25(11):1078-80.

PMID:
17072136
26.

Comparison of real-time PCR and pyrosequencing for typing Bordetella pertussis toxin subunit 1 variants.

Storm M, Advani A, Pettersson M, Hallander HO, Bondeson K.

J Microbiol Methods. 2006 Apr;65(1):153-8. Epub 2005 Aug 10.

PMID:
16095736
27.

Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.

Hallander HO, Gustafsson L, Ljungman M, Storsaeter J.

Vaccine. 2005 Nov 16;23(46-47):5359-64. Epub 2005 Jul 1.

PMID:
16051400
28.

Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies.

Caro V, Njamkepo E, Van Amersfoorth SC, Mooi FR, Advani A, Hallander HO, He Q, Mertsola J, Riffelmann M, Vahrenholz C, Von König CH, Guiso N.

Microbes Infect. 2005 Jun;7(7-8):976-82.

PMID:
15994109
29.

Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.

Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM.

J Clin Microbiol. 2005 Jun;43(6):2856-65.

30.

Analysis of Bordetella pertussis populations in European countries with different vaccination policies.

van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, von König CH, Riffelmann M, Vahrenholz C, Guiso N, Caro V, Njamkepo E, He Q, Mertsola J, Mooi FR.

J Clin Microbiol. 2005 Jun;43(6):2837-43.

31.
32.

Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden.

Olin P, Hallander HO.

Euro Surveill. 1999 Dec;4(12):128-129.

PMID:
12631878
33.

Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

Hallander HO, Paniagua M, Espinoza F, Askelöf P, Corrales E, Ringman M, Storsaeter J.

Vaccine. 2002 Nov 22;21(1-2):138-45.

PMID:
12443672
34.

How to make sense of pertussis immunogenicity data.

Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J.

Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S288-91. Review.

PMID:
11709761
35.

The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network.

Edmunds WJ, Pebody RG, Aggerback H, Baron S, Berbers G, Conyn-van Spaendonck MA, Hallander HO, Olander R, Maple PA, Melker HE, Olin P, Fievret-Groyne F, Rota C, Salmaso S, Tischer A, von-Hunolstein C, Miller E.

Epidemiol Infect. 2000 Aug;125(1):113-25. Erratum in: Epidemiol Infect 2001 Apr;126(2):331.

36.

Towards European urinalysis guidelines. Introduction of a project under European Confederation of Laboratory Medicine.

Kouri TT, Gant VA, Fogazzi GB, Hofmann W, Hallander HO, Guder WG.

Clin Chim Acta. 2000 Jul;297(1-2):305-11.

PMID:
10841931
37.

Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster.

Tiru M, Hallander HO, Gustafsson L, Storsaeter J, Olin P.

Vaccine. 2000 Apr 28;18(21):2295-306.

PMID:
10717350
38.

Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae and persistent cough in children.

Hallander HO, Gnarpe J, Gnarpe H, Olin P.

Scand J Infect Dis. 1999;31(3):281-6.

PMID:
10482058
39.

Microbiological and serological diagnosis of pertussis.

Hallander HO.

Clin Infect Dis. 1999 Jun;28 Suppl 2:S99-106. Review.

PMID:
10447026
40.
41.

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.

Storsaeter J, Hallander HO, Gustafsson L, Olin P.

Vaccine. 1998 Dec;16(20):1907-16.

PMID:
9796042
42.

Catch-up primary vaccination with acellular pertussis vaccines in 3-4-year-old children--reactogenicity and serological response.

Wärngård O, Nilsson L, Fåhraeus C, Gustafsson L, Hallander HO, Olin P, Storsaeter J.

Vaccine. 1998 Mar;16(5):480-4.

PMID:
9491502
43.

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.

Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H.

Lancet. 1997 Nov 29;350(9091):1569-77. Erratum in: Lancet 1998 Feb 7;351(9100):454.

PMID:
9393335
44.
45.

Validation of nested Bordetella PCR in pertussis vaccine trial.

Reizenstein E, Lindberg L, Möllby R, Hallander HO.

J Clin Microbiol. 1996 Apr;34(4):810-5.

46.

[Compare pertussis vaccines--but do it accurately].

Olin P, Hallander HO.

Lakartidningen. 1996 Feb 14;93(7):603-4. Swedish. No abstract available.

PMID:
8642927
47.

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J.

N Engl J Med. 1996 Feb 8;334(6):349-55. Erratum in: N Engl J Med 1996 May 2;334(18):1207.

48.

Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage.

Romanus V, Hallander HO, Wåhlén P, Olinder-Nielsen AM, Magnusson PH, Juhlin I.

Tuber Lung Dis. 1995 Aug;76(4):300-10.

PMID:
7579311
49.

Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model.

Reizenstein E, Hallander HO, Blackwelder WC, Kühn I, Ljungman M, Möllby R.

J Immunol Methods. 1995 Jun 28;183(2):279-90.

PMID:
7602150
50.

[Diagnosis of distal urinary disorders--a reply].

Bengtsson S, Hallander HO, Forsum U.

Lakartidningen. 1995 May 10;92(19):1987-8. Swedish. No abstract available.

PMID:
7752737

Supplemental Content

Loading ...
Support Center